Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial.
Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments. Elastagen has developed a synthetic version of the elastin protein which is identical to that naturally present in the human body.
Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling, skin tissue repair and wound healing, and, surgical glues / sealants.
Elastagen has a strong commitment to scientific and clinical excellence in the development of its tropoelastin based products, and has received endorsements of its scientific and clinical excellence from the NSW Department of Health.
Elastagen began operations in 2005 following seed funding from ATP Innovations and the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney, The company started the commercially and clinically focused phase of its business in August 2008, following Series A financing by leading Australian venture investors including GBS Ventures and Brandon Capital Partners together with ATP Innovations.
Elastagen’s operations have expanded from its Australian base to include production in Europe, clinical operations in the UK, and a product development program in collaboration with groups in Europe and the US.